Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2026)

Xeris Biopharma Holdings has reported Gross Margin for 7 years, with the latest figure at 87.28% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 180.0% year-over-year to 87.28%; the trailing twelve-month figure through Mar 2026 stood at 85.89% (up 368.0% YoY), and the FY2025 full-year result was 85.41%, up 355.0% from the prior year.
• Gross Margin for Q1 2026 stood at 87.28%, roughly flat from 87.24% in the prior quarter.
• The five-year high for Gross Margin was 87.28% in Q1 2026, with the low at 71.58% in Q1 2022.
• Historically, Gross Margin has averaged 82.52% across 5 years, with a median of 83.37% in 2025.
• Annual changes were most pronounced in 2022 — Gross Margin surged 1898 bps — and 2024, when it tumbled 808 bps.
• Xeris Biopharma Holdings' Gross Margin stood at 81.02% in 2022, then increased by 2 bps to 82.95% in 2023, then gained by 2 bps to 84.23% in 2024, then climbed by 4 bps to 87.24% in 2025, then grew by 0 bps to 87.28% in 2026.
• The last three Gross Margin figures came in at 87.28% (Q1 2026), 87.24% (Q4 2025), and 85.22% (Q3 2025), per Business Quant data.